A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Open accessAbstract
Importance: Cerebrospinal fluid (CSF) core Alzheimer disease (AD) biomarkers have shown an excellent capacity for the in vivo detection of AD. Previous studies have shown that CSF levels of phosphorylated tau (p-tau) also correlate with tau pathology in frontotemporal lobar degeneration (FTLD) after accounting for AD copathology. Objective: To develop an algorithm based on core AD CSF measures to exclude cases with AD pathology and then differentiate between FTLD-tau and FTLD transactive response DNA-binding protein of approximately 43kDa (FTLD-TDP). Design, Setting, and Participants: A case-control study at the University of Pennsylvania. Participants were selected from a database of 1796 patients included between 1992 and 2016 with different neurodegenerative diseases with available CSF. Three patient cohorts were included: a cohort of patients with sporadic, autopsy-confirmed FTLD and AD (n = 143); a cohort of patients with frontotemporal degeneration (FTD) with TDP-associated or tau-associated mutations (n = 60); and a living cohort of patients with syndromes highly predictive of FTLD (progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis; n = 62). Main Outcomes and Measures: Cerebrospinal fluid values of amyloid β1-42 (Aβ1-42), total tau (t-tau), and p-tau obtained using the INNO-BIA AlzBio3 (xMAP; Luminex) assay or INNOTEST enzyme-linked immunosorbent assay transformed using a previously validated algorithm. Sensitivities and specificities for differentiating AD from FTLD groups were calculated. Results: This autopsy cohort included FTLD-tau (n = 27; mean [SD] age at onset, 60.8 [9.7] years), FTLD-TDP (n = 13; mean [SD] age at onset, 62.4 [8.5] years), AD (n = 89, mean [SD] age at onset, 66.5 [9.7] years); and mixed FTLD-AD (n = 14, mean [SD] age at onset, 70.6 [8.5] years).The p-tau/Aβ1-42 ratio showed an excellent diagnostic accuracy to exclude AD cases in the autopsy cohort with single neurodegenerative pathologies (area under the curve [AUC], 0.98; 95% CI, 0.96-1.00). Cerebrospinal fluid p-tau levels showed a good AUC (0.87; 95% CI, 0.73-1.00) for discriminating pure FTLD-TDP from pure FTLD-tau. The application of an algorithm using cutpoints of CSF p-tau to Aβ1-42 ratio and p-tau allowed a good discrimination of pure FTLD-TDP cases from the remaining FTLD-tau and mixed FTLD cases. The diagnostic value of this algorithm was confirmed in an independent cohort of living patients with progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis (AUC, 0.9; 95% CI, 0.81-0.99). However, the algorithm was less useful in FTD cases carrying a pathogenic mutation (AUC, 0.58; 95% CI, 0.38-0.77) owing to elevated p-tau levels in TDP-associated mutation carriers. Conclusions and Relevance: Alzheimer disease CSF core biomarkers can be used with high specificity for the in vivo identification of patients with pure FTLD-TDP and FTLD-tau when accounting for comorbid AD and genetic status.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plasma biomarkers are powerful diagnostic and prognostic clinical tools.
“Plasma biomarkers are powerful diagnostic and prognostic clinical tools. 1”
From Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease (2021) · cites this paper as [1]
The Biofluid Collection and Analysis and Discussion sections describe cerebrospinal fluid (CSF) biomarkers and their diagnostic use in distinguishing neurodegenerative pathologies. The Discussion also notes that CSF neurofilament light correlates with disease progression, but the paper does not establish that plasma biomarkers are diagnostic or prognostic clinical tools. Page numbers are unavailable in our copy. (LLM, conf=0.83)
Experimental — accuracy not yet measuredBoth t-tau and NfL may be useful for the diagnosis and prognosis of FTLD.
“The combination of CSF t-tau and NfL discriminated between early onset AD and FTLD, 9 and both analytes may be useful for the diagnosis and prognosis of FTLD.1,[10][11][12]”
From Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease (2021) · cites this paper as [1]
The Discussion (page unavailable) says NfL is elevated in FTD and correlates with disease progression, supporting its potential prognostic use, but cautions that it lacks disease specificity. The paper uses t-tau among biomarkers that help exclude AD in FTLD-related syndromes; it does not establish t-tau as a prognostic marker for FTLD. (LLM, conf=0.86)
Experimental — accuracy not yet measuredElevated CSF total tau and phosphorylated tau are regarded as markers of neurodegeneration and tau pathology in Alzheimer disease and are used clinically to raise diagnostic certainty; with CSF Aβ42 they are recommended in the Alzheimer's Association Appropriate Use Criteria for CSF testing in AD diagnosis.
“Elevated CSF levels of t-tau and p-tau are considered markers of neurodegeneration and tau pathology in AD and are used in the clinical setting to increase the diagnostic certainty of AD, 1 and together with CSF Aβ42 recommended for diagnostic use in the Alzheimer's Association Appropriate Use Criteria for CSF testing in the diagnosis of AD. 35”
From Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease (2021) · cites this paper as [1]
Split into 2 atoms — 1 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredPatients were included if they had either a post mortem neuropathologic diagnosis or an in vivo CSF analyte profile suggestive of the underlying neuropathology based on cutoffs previously validated in autopsy series.
“Patients were included if they had either a post mortem neuropathologic diagnosis or an in vivo CSF analyte profile suggestive of the underlying neuropathology based on cutoffs previously validated in autopsy series.”
From Automatic classification of AD pathology in FTD phenotypes using natural speech (2024) · cites this paper as [29]
The Autopsy Cohort and Statistical Analysis sections (pages not provided) describe neuropathologically diagnosed patients and CSF cutoffs derived from the autopsy cohort; the Validation section applies the algorithm to living patients. The paper therefore supports the basis for an in vivo CSF profile, but it does not establish the claimed either/or inclusion rule: its living validation cohort was selected by clinical syndrome, not by a qualifying CSF profile. (LLM, conf=0.83)
Experimental — accuracy not yet measuredCo-occurring AD pathology is a frequent clinical FTD manifestation.
“which is a frequent clinical FTD manifestation [90].”
Lower CSF p-tau could discriminate FTD-TDP from FTD-tau in sporadic pure FTD cases after excluding AD.
“Lower CSF p‐tau could discriminate FTD‐TDP from FTD‐tau in sporadic pure FTD cases after excluding AD.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [67]
Many biomarker studies in FTD may be confounded by co-occurring secondary AD pathology.
“Of note, many biomarker studies in FTD may be confounded by co‐occurring secondary AD pathology.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [67]
The value of CSF tau measurements is limited to pure cases of FTLD (e.g., without copathologies).
“Other studies have shown that the value of CSF tau measurements is limited to pure cases of FTLD (e.g., without copathologies).”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [67]
The performance of CSF p-tau181 to discriminate between FTD pathological subtypes (FTLD-tau vs. FTLD-TDP) was considerably reduced when mutation carriers were analyzed separately (AUCs of 0.87 in sporadic pure cases vs. 0.58 in genetic cases).
“the performance of CSF p‐tau181 to discriminate between FTD pathological subtypes (i.e., FTLD‐tau vs. FTLD‐TDP) was considerably reduced when mutation carriers were analyzed separately (AUCs of 0.87 in sporadic pure cases vs. 0.58 in genetic cases). 61 , 67”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · see citing works
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · see citing works
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,992 · see citing works
Self-citationAppelhof, B., Bakker, C., den IJssel, J. C. L. V. D., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,773 · see citing works
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,374 · see citing works
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Self-citationQualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., Swieten, J. C. V., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,061 · see citing works
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · see citing works
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works
Self-citationMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · see citing works
Self-citationStrong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., Mclaughlin, P., Snowden, J., Mioshi, E., Roberts-South, A., Benatar, M., HortobáGyi, T., et al. (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2016.1267768 · Cited by 909 · see citing works
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586 · see citing works
Ashwal, S., Bale, J. F., Coulter, D. L., Eiben, R., & Garg, B. P. (2006) · Annals of Neurology · doi:10.1002/(issn)1531-8249 · Cited by 514 · see citing works
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478 · see citing works
Self-citationOlsson, A., Vanderstichele, H., Andreasen, N., Meyer, G. D., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 424 · see citing works
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · see citing works
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine
Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Deerlin, V. M. V., Lee, V. M. ‐., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 262 · see citing works
Self-citationScherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249 · see citing works
Toledo, J. B., Van Deerlin, V. M., Lee, E. B., Suh, E., Baek, Y., Robinson, J. L., Xie, S. X., McBride, J., Wood, E. M., Schuck, T., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.06.003 · Cited by 234 · see citing works
Self-citationCerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease
Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228 · see citing works
Self-citationCSF biomarkers in frontotemporal lobar degeneration with known pathology
Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216 · see citing works
Self-citation18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Williamson, D., Borchert, R. J., Sami, S. A. K., Cope, T., Bevan-Jones, W. R., Jones, P. S., et al. (2016) · Brain · doi:10.1093/brain/aww340 · Cited by 207 · see citing works
Deep clinical and neuropathological phenotyping of P ick disease
Irwin, D. J., Brettschneider, J., McMillan, C. T., Cooper, F. I., Olm, C. A., Arnold, S. E., Deerlin, V. M. V., Seeley, W. W., Miller, B. L., Lee, E. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24559 · Cited by 204 · see citing works
Self-citationPathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190 · see citing works
CSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · see citing works
Self-citationCerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works
Self-citationDevelopment and Validation of Pedigree Classification Criteria for Frontotemporal Lobar Degeneration
Wood, E. M., Falcone, D., Suh, E. R., Irwin, D. J., Chen‐Plotkin, A. S., Lee, E. B., Xie, S. X., Deerlin, V. M. V., & Grossman, M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3956 · Cited by 141 · see citing works
Self-citationCSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration
Alcolea, D., Vilaplana, E., Suárez-Calvet, M., Illán-Gala, I., Blesa, R., Clarimón, J., Lladó, A., Sánchez-Valle, R., Molinuevo, J. L., García-Ribas, G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004088 · Cited by 123 · see citing works
Self-citationDistinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
Pera, M., Alcolea, D. A., Sánchez‐Valle, R., Guardia‐Laguarta, C., Colom‐Cadena, M., Badiola, N., Suárez‐Calvet, M., Lladó, A., Barrera-Ocampo, A. A., Falla, D. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1062-9 · Cited by 120 · see citing works
Self-citationIrwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Van Deerlin, V., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.26 · Cited by 116 · see citing works
Self-citationReduced CSF p-Tau <sub>181</sub> to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113 · see citing works
Self-citationMultisite assessment of NIA‐AA guidelines for the neuropathologic evaluation of Alzheimer's disease
Montine, T. J., Monsell, S. E., Beach, T. G., Bigio, E. H., Bu, Y., Cairns, N. J., Frosch, M., Henriksen, J., Kofler, J., Kukull, W. A., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.07.492 · Cited by 113 · see citing works
Self-citationTeunissen, C. E., Elias, N., Koel‐Simmelink, M. J. A., Durieux‐Lu, S., Malekzadeh, A., Pham, T. V., Piersma, S. R., Beccari, T., Meeter, L. H. H., Dopper, E. G. P., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.12.004 · Cited by 103 · see citing works
Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis
Grossman, M., Elman, L., McCluskey, L., McMillan, C. T., Boller, A., Powers, J., Rascovsky, K., Hu, W., Shaw, L., Irwin, D. J., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6064 · Cited by 94 · see citing works
Self-citationMcMillan, C. T., Irwin, D. J., Nasrallah, I., Phillips, J. S., Spindler, M., Rascovsky, K., Ternes, K., Jester, C., Wolk, D. A., Kwong, L. K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1640-3 · Cited by 87 · see citing works
Self-citationIrwin, D. J., Lleó, A., Xie, S. X., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2017) · Annals of Neurology · doi:10.1002/ana.24996 · Cited by 67 · see citing works
Self-citationBiomarkers in the primary progressive aphasias
Grossman, M. (2014) · Aphasiology · doi:10.1080/02687038.2014.929631 · Cited by 23 · see citing works
Self-citationBalasa, M., Dídac Vidal-piñeiro, A., Lladó, A., Antonell, A., Bosch, B., Castellanos, F., Bargalló, N., Bartrés‐Faz, D., Molinuevo, J. L., & Sánchez‐Valle, R. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111949 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Irwin DJ, Brettschneider J, McMillan CT, et al. Deep clinical and neuropathological phenotyping of Pick disease. Ann Neurol. 2016;79(2):272-287.
Cited by
Sorted by citations
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241 · see citing works
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183 · see citing works
Self-citationPlasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease
Illán-Gala, I., Lleo, A., Karydas, A., Staffaroni, A. M., Zetterberg, H., Sivasankaran, R., Grinberg, L. T., Spina, S., Kramer, J. H., Ramos, E. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011226 · Cited by 150 · see citing works
Self-citationBiomarkers for diseases with TDP-43 pathology
Steinacker, P., Barschke, P., & Otto, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.10.003 · Cited by 57 · see citing works
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52 · see citing works
Self-citationLexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology
Cho, S., Cousins, K. A. Q., Shellikeri, S., Ash, S., Irwin, D. J., Liberman, M. Y., Grossman, M., & Nevler, N. (2022) · Neurology · doi:10.1212/wnl.0000000000200581 · Cited by 51 · see citing works
Self-citationBolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36 · see citing works
Novel <scp>CSF</scp> biomarkers to discriminate <scp>FTLD</scp> and its pathological subtypes
del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y. A., van Swieten, J. C., Watts, K., Paciotti, S., Beccari, T., Hu, W., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.629 · Cited by 30 · see citing works
Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?
Lleó, A., Parnetti, L., Belbin, O., & Wiltfang, J. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.01.019 · Cited by 26 · see citing works
Self-citationCSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201202 · Cited by 25 · see citing works
Self-citationAPP‐derived peptides reflect neurodegeneration in frontotemporal dementia
Illán‐Gala, I., Pegueroles, J., Montal, V., Alcolea, D., Vilaplana, E., Bejanin, A., Borrego‐Écija, S., Sampedro, F., Subirana, A., Sánchez‐Saudinós, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50948 · Cited by 20 · see citing works
Self-citationAutomatic classification of AD pathology in FTD phenotypes using natural speech
Cho, S., Olm, C. A., Ash, S., Shellikeri, S., Agmon, G., Cousins, K. A. Q., Irwin, D. J., Grossman, M., Liberman, M., & Nevler, N. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13748 · Cited by 13 · see citing works
Self-citation
- Authors
- Lleó, A., Irwin, D. J., Illán-Gala, I., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- University of Pennsylvania Health System (US)
- Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, Barcelona, Spain.
- University of Pennsylvania (US)
- Alzheimer’s Disease Core Center, University of Pennsylvania Perelman School of Medicine, Philadelphia
- Corresponding author
- Grossman, Murray
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-06-01
- Volume
- 75
- Issue
- 6
- Pages
- 738
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC5885205
- OpenAlex
- W2794239764
- Cited by
- 71
- References
- 40
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 13 · 2021: 6 · 2020: 9 · 2019: 11 · 2018: 5
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wyncote Foundation
- National Institutes of Health
- Instituto de Salud Carlos III
- National Institute on Aging (P30AG010124, P01AG017586, K01AG043503)
- National Institute of Neurological Disorders and Stroke (K23NS088341)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- frontotemporal lobar degeneration, FTLD-tau, FTLD-TDP, Alzheimer's disease, cerebrospinal fluid biomarkers, phosphorylated tau, amyloid-beta 42, diagnostic algorithm, differential diagnosis, progressive supranuclear palsy, tau mutations, neurodegeneration
- MeSH terms
- Aged, Aged, 80 and over, Algorithms, Female, Humans, Male, Peptide Fragments, Biomarkers, Case-Control Studies, Databases, Factual, Amyloid beta-Peptides, tau Proteins, Frontotemporal Lobar Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
